Pfizer Shares Jump 12% as Net Profit Surges 85%

Shares of Pfizer surged by 11.91% to ₹4,995.85 in today’s trading session after the drugmaker reported its March quarter earnings (Q4FY25). Net profit in the reported quarter surged by 85% to ₹330.94 crore, against ₹178.86 crore in the year-ago period.

Sales jumped by 8% to ₹591.91 crore in Q4FY25 compared to ₹546.63 crore in the corresponding period a year ago.

The board announced a dividend of ₹165 for FY25. Pfizer said, “The Board of Directors, at their meeting held on May 19, 2025, have recommended a final dividend of Rs 35 per equity share of Rs 10 each (350 per cent) and a special dividend of Rs 100 per equity share of Rs 10 each (1000 per cent) in view of 75th year of Pfizer in India and a special dividend of Rs 30 per equity share of Rs 10 each (300 per cent) in view of the gain on transfer of assignment of leasehold land and building constructed on such land thereon, totaling to a dividend of Rs 165 per equity share Rs 10 each (1650 per cent) for the financial year ended March 31, 2025.”

The scrip traded higher than the 5-day, 10-day and 30-day simple moving averages (SMAs) but lower than the 20-day, 50-, 100-, 150-day and 200-day SMAs. The 14-day relative strength index (RSI) was reported at 83.93. Notably, a level below 30 is defined as oversold while a value above 70 is considered overbought.

Arpit Beriwal, Manager – Derivatives Analyst (Equity Research) at Motilal Oswal Financial Services told Business Today, “The next leg of rally can be seen towards Rs 5,200, which would be a major hurdle zone and those who have bought the stock at lower levels can consider exiting. Immediate support will be at Rs 4,800.”

Founded in 1849, Pfizer is an American pharmaceutical company that manufactures markets, trades and exports pharmaceutical products.